Outlook Therapeutics (OTLK) remained on investors’ radar as Wall Street reacted to the U.S. Food and Drug Administration’s approval of its lead eye therapy following three regulatory setbacks.BTIG upgraded the stock to ‘Buy’ from ‘Neutral’ and set a price target of $4, a 247% upside potential from…
Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and Regulatory EvaluationCompany Launches Commercial Franchise Positioned to Establish a New Standard as…
Outlook Therapeutics (OTLK) was back in the spotlight on Thursday as Wall Street looked ahead to a crucial U.S. Food and Drug Administration (FDA) decision on its therapy to treat wet age-related macular degeneration (Wet AMD), with the regulator reviewing the company’s biologics license applicatio…
Outlook Therapeutics (OTLK) was back in the spotlight on Thursday as Wall Street looked ahead to a crucial U.S. Food and Drug Administration (FDA) decision on its therapy to treat wet age-related macular degeneration (Wet AMD), with the regulator reviewing the company’s biologics license applicatio…
On June 26, 2026, Nasdaq notified the company that it regained compliance with Listing Rule 5550(a)(2) after its closing bid price was at or above $1.00 for ten consecutive business days from June 11–25, 2026. This follows a February 18, 2026 notice related to a minimum bid price deficiency; Nasdaq…
